Economic Burden of Propionic Acidemia by Age Stratum in the United States

Author(s)

Banerjee G1, Mu F2, Cheng M2, Cook E2, Zhang A2, Lan JJ2, Zou L2, Sikirica V3
1ModernaTX, Inc., Cambridge, MA, USA, 2Analysis Group, Inc., Boston, MA, USA, 3Moderna, Inc., Cambridge, MA, USA

OBJECTIVES: To estimate the economic burden of propionic acidemia (PA), a rare inherited metabolic disorder, in the United States by age stratum.

METHODS: A retrospective matched cohort study was conducted using IQVIA PharMetrics® Plus claims data (10/2015-06/2022) comparing patients with PA to patients without PA (controls). Patients were matched 1:1 within each age stratum (0-2, 3-6, 7-12, 13-17, and 18+ years) on factors including age, year, month, sex, region, and insurance. All-cause healthcare resource utilization (HRU) per patient-year (PPY) and annualized costs were described and compared between patients with and without PA within age strata.

RESULTS: This study included 191 patients with PA and their matched controls (by age stratum: 0-2 years, n=32 pairs; 3-6, n=32; 7-12, n=36; 13-17, n=24; 18+, n=106). Most patients had commercial insurance (91.1%) and half were female (49.7%). Patients with PA had significantly higher HRU rates and total costs compared to controls across age strata. Patients with PA had 0.5-2.3 hospitalizations, 0.7-1.9 emergency visits, and 15.3-41.3 outpatient visits PPY across age strata, leading to a 10.4-78.6, 2.2-4.5, and 1.9-8.2 fold higher rate compared to controls, respectively (all p<0.001). Mean (median) total healthcare costs were $88,523 ($16,929) among patients with PA, with medical costs accounting for about 68% of total costs ($60,385 [$14,674]), primarily driven by hospitalization costs ($40,621 [$3,254]). Total mean annualized cost difference was highest for patients with PA at 0-2 years vs. controls at $205,883 ($209,332 [$42,991] vs. $3,449 [$2,711]) and lowest at 7-12 years at $20,169 ($21,797 [$11,487] vs. $1,628 [$617]); adults also showed a significant difference at $75,095 ($79,336 [$21,168] vs. $4,241 [$1,437]) (all p<0.001).

CONCLUSIONS: Patients with PA had significant HRU and economic burden compared to controls without PA across age strata, primarily driven by a higher burden of hospitalization. Development of efficacious treatments for PA to help reduce the burden is needed.

Conference/Value in Health Info

2023-11, ISPOR Europe 2023, Copenhagen, Denmark

Value in Health, Volume 26, Issue 11, S2 (December 2023)

Code

EE699

Topic

Economic Evaluation, Study Approaches

Disease

Diabetes/Endocrine/Metabolic Disorders (including obesity), Rare & Orphan Diseases

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×